Synergistic Inhibition of Survival Proliferation and Migration of U87 Cells with a Combination of LY341495 and Iressa

摘要

Glioblastomas exploit various molecular pathways to promote glutamate- dependent growth by activating the AMPA (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid) receptor, the group II metabotropic glutamate receptor, mGluR, and the epidermal growth factor receptor, EGFR. We hypothesized that targeting more than one of these pathways would be more effective in inhibiting glutamate-dependent growth. Using a model of U87 cell line, we show that blocking glutamate release by Riluzole inhibits cell proliferation. Glutamate-dependent growth is effectively inhibited by a combination of Iressa, an inhibitor of EGFR activation and , a group II mGluR inhibitor. Treatment of U87 cells with a combination of Iressa and inhibits proliferation as indicated by Ki-67 staining, induces apoptosis and inhibits migration of U87 cells more effectively than the treatment by Iressa or alone. These results demonstrate that a combinatorial therapy with Iressa and is more effective due to synergistic effects of these drugs in inhibiting the growth of glioblastoma.